PUHY DOROTHY E
Known title: DirectorCIK: 0001200493
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
AZTA Featured in Volatile Stock List. Azenta Inc. was included in a recent article discussing volatile stocks with promising prospects. The stock is currently trading within its 52-week range, with analysts maintaining an average price target of $37.00. This mention highlights the company's status as a high-beta asset in the current market environment.
Transaction History
| MDXG | ▲ Buy | Grant | 50,913 | $185K | 6/10/2026 | View on chart |
| MDXG | ▲ Buy | Grant | 28,609 | $185K | 6/18/2025 | View on chart |
| MDXG | ▲ Buy | Grant | 28,988 | $210K | 6/5/2024 | View on chart |
| AZTA | ▲ Buy | Grant | 3,604 | $0 | 2/13/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
MiMedx Wins Favorable Court Ruling on AXIOFILL Classification
A U.S. federal court ruled that MiMedx’s product AXIOFILL is not subject to the FDA’s regulatory classification that had limited its use. The decision removes a major regulatory hurdle for the company’s regenerative medicine line. The ruling could improve market perception and support future sales. The stock is currently near its 12‑month support level.
MiMedx Wins Favorable Court Ruling on AXIOFILL Classification. A U.S. federal court ruled that MiMedx’s product AXIOFILL is not subject to the FDA’s regulatory classification that had limited its use. The decision removes a major regulatory hurdle for the company’s regenerative medicine line. The ruling could improve market perception and support future sales. The stock is currently near its 12‑month support level.